Cleared Traditional

K191533 - ADVIA Centaur Testosterone II (TSTII)

K191533 is the FDA 510(k) clearance for ADVIA Centaur Testosterone II (TSTII) by Siemens Healthcare Diagnostics, Inc.. It is a Class 1 Chemistry device (product code CDZ) cleared through the Traditional 510(k) pathway after a 79-day FDA review.

K191533 · Siemens Healthcare Diagnostics, Inc. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2019
Decision
79d
Days
Class 1
Risk

K191533 is an FDA 510(k) clearance for the ADVIA Centaur Testosterone II (TSTII), ADVIA Centaur SHBG. Classified as Radioimmunoassay, Testosterones And Dihydrotestosterone (product code CDZ), Class I - General Controls.

Submitted by Siemens Healthcare Diagnostics, Inc. (Tarrytown, US). The FDA issued a Cleared decision on August 28, 2019 after a review of 79 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1680 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Siemens Healthcare Diagnostics, Inc. devices

Submission Details

510(k) Number K191533 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 10, 2019
Decision Date August 28, 2019
Days to Decision 79 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
9d faster than avg
Panel avg: 88d · This submission: 79d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code CDZ Radioimmunoassay, Testosterones And Dihydrotestosterone
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 862.1680
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.

Regulatory Peers - CDZ Radioimmunoassay, Testosterones And Dihydrotestosterone

All 53
Devices cleared under the same product code (CDZ) and FDA review panel - the closest regulatory comparables to K191533.
Elecsys Testosterone II
K211685 · Roche Diagnostics · May 2022
LIAISON Testosterone xt
K201908 · DiaSorin, Inc. · Oct 2020
ACTIVE® Free Testosterone RIA
K191350 · Immunotech S.R.O. · Dec 2019
IDS SHBG
K190121 · Immunodiagnostic Systems , Ltd. · Jun 2019
FastPack IP Sex Hormone Binding Globulin Immunoassay
K182521 · Qualigen, Inc. · Jan 2019
Free Testosterone AccuBind ELISA Test System
K181017 · Monobind, Inc. · Jul 2018